Amarin Corp Plc (AMRN)

[couldbebetter]

No doubt the potential market for Vascepa in China is massive and its
health care system will be overwhelmed by people with Type-2 Diabetes.
Besides a western style diet people in China are subjected to air-pollution
and many are smokers. (The COPD indication could also be huge.)

Just as the AAPL I-Phone is a big seller in China so should Vascepa if it
is marketed properly. The price will be substantially less than in the US
but the market is massive. Because of issues with the quality of Chinese
food, (many fear being poisoned by bad food) Vascepa would have to marketed
as not only safe and effective, but having no contaminants as might be had
in fish or fish oil.

Being that any approval may be years away, it is off the investor radar.
However, to a potential aquirer, especially one with experience in the
Asian medical markets, this may be a real incentive to buy AMRN.